ACADIA Pharmaceuticals AI Stock Analysis
ACADIA Pharmaceuticals (0A4W) AI Stock Analysis
ACADIA Pharmaceuticals
(LSE:0A4W)
No summary available
ACADIA Pharmaceuticals (0A4W) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $3.08B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 8.4
- Beta (1Y)
- 0.09
- Revenue Growth
- 14.82%
- EPS Growth
- 36.49%
- Country
- UK
- Employees
- 797
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ACADIA Pharmaceuticals Business Overview & Revenue Model
Company Description
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of...
ACADIA Pharmaceuticals Earnings Call Summary
The call conveyed strongly positive commercial momentum, with record DAYBUE sales, substantial STIX adoption, European approval, extended patent protection, continued NUPLAZID growth, and a strong cash position. The pipeline outlook was constructive, supported by a clear 60-milligram remlifanserin efficacy signal, favorable safety findings, and multiple development programs, although the RADIANT primary endpoint narrowly missed statistical significance and the company is managing a leadership transition and timing-related NUPLAZID guidance constraints. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Acadia now expects total revenues of $1.265 billion to $1.295 billion for 2026, DAYBUE full year global net sales of $505 million to $520 million, NUPLAZID full year net sales of $760 million to $775 million, DAYBUE gross-to-net of approximately 23% to 24%, NUPLAZID gross-to-net of approximately 22% to 23%, R&D expenses of $325 million to $340 million, and SG&A expenses of $665 million to $685 million; it remains confident in reaching $700 million in DAYBUE sales by the end of 2028 and approximately $1 billion in NUPLAZID net sales by the end of 2028, expects Phase II results from ILLUMERA in the fourth quarter of 2027, an additional NORLIGHT data readout in the second half of 2027, an expected 2027 regulatory submission for DAYBUE in Japan, and a targeted launch in 2028.
ACADIA Pharmaceuticals Risk Analysis
ACADIA Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. ACADIA Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksACADIA Pharmaceuticals Peers Comparison
Overall Rating
HRMY77Outperform
PTCT64Neutral
BHVN59Neutral
IMMX51Neutral
XENE46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $1.94B | 10.75 | 18.55% | ― | 19.79% | -4.89% | |
| 64Neutral | $5.03B | -45.98 | 57.10% | ― | -35.05% | -113.73% | |
| 59Neutral | $1.95B | -3.34 | -2271.87% | ― | ― | 49.16% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $603.45M | -8.57 | -24.93% | ― | ― | -5.65% | |
| 46Neutral | $3.71B | -8.03 | -39.80% | ― | -100.00% | -21.09% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0A4W | ACADIA Pharmaceuticals Inc. | 26.87 | 8.25 | 44.31% | |
| PTCT | PTC Therapeutics | 60.23 | -18.24 | -23.24% | |
| XENE | Xenon Pharmaceuticals | 37.75 | -3.41 | -8.28% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 33.11 | -1.20 | -3.50% | |
| IMMX | Immix Biopharma, Inc. | 7.11 | 2.78 | 64.20% | |
| BHVN | Biohaven Ltd. | 12.90 | 3.21 | 33.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
